Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
KLHL9 CRISPR/Cas9 KO Plasmid (m): sc-433908
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- KLHL9 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the KLHL9 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
KLHL9 CRISPR/Cas9 KO Plasmid (m) | sc-433908 | 20 µg | $397.00 |
Overview
Klhl9 encodes the mouse KLHL9 protein, a BTB–BACK–Kelch family substrate adaptor that cooperates with CUL3-RBX1 E3 ubiquitin ligase complexes to promote ubiquitination and proteasome-dependent turnover of specific client proteins. Through this ubiquitin-mediated proteostasis control, KLHL9 contributes to regulation of protein quality control, cell-cycle–linked processes, and signaling outputs that depend on timely substrate clearance. Perturbation of CUL3–KLHL adaptors is broadly relevant to dysregulated ubiquitin pathways implicated in neurodevelopment, neuromuscular biology, and cancer-associated proteome remodeling, making Klhl9 a useful node for studying ubiquitin–proteasome system specificity. In mouse models, loss-of-function approaches enable dissection of how KLHL9-dependent substrate selection shapes downstream cellular phenotypes in defined tissues or cell types.
KLHL9 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Klhl9 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Klhl9 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Klhl9 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish KLHL9 protein expression.
This CRISPR knockout system enables efficient generation of Klhl9-deficient cell models for investigation of KLHL9 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Klhl9 exon(s) critical for KLHL9 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Klhl9 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by KLHL9 CRISPR/Cas9 KO Plasmid (m) and KLHL9 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Klhl9 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by KLHL9 HDR Plasmid (m) and KLHL9 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Klhl9 homology arms to support homology-directed repair at defined Klhl9 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.